Sutro Biopharma (NASDAQ:STRO – Get Free Report) was upgraded by Barclays to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.
Other analysts have also issued research reports about the stock. Citizens Jmp lifted their price target on shares of Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a research note on Thursday, April 23rd. Mizuho set a $50.00 price target on shares of Sutro Biopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Citigroup restated an “outperform” rating on shares of Sutro Biopharma in a research note on Friday, April 17th. Leerink Partners set a $43.00 price target on shares of Sutro Biopharma and gave the stock an “outperform” rating in a research note on Friday, May 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Friday, May 8th. Four analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $49.11.
Check Out Our Latest Stock Analysis on Sutro Biopharma
Sutro Biopharma Stock Down 0.2%
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The firm had revenue of $14.52 million for the quarter, compared to the consensus estimate of $8.89 million. Equities analysts expect that Sutro Biopharma will post -8.81 earnings per share for the current fiscal year.
Institutional Trading of Sutro Biopharma
Institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new stake in Sutro Biopharma during the third quarter valued at $152,000. Stempoint Capital LP bought a new stake in Sutro Biopharma during the first quarter valued at $580,000. State of Tennessee Department of Treasury bought a new stake in Sutro Biopharma during the fourth quarter valued at $86,000. Bridgeway Capital Management LLC increased its stake in Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in Sutro Biopharma during the second quarter valued at $82,000. Institutional investors own 96.99% of the company’s stock.
Sutro Biopharma Company Profile
Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.
Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.
Featured Articles
- Five stocks we like better than Sutro Biopharma
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
